Mambalgin-1 vs Apratoxin A
Head-to-head comparison of Mambalgin-1 (Mambalgin-1 from Dendroaspis polylepis venom) and Apratoxin A (Apratoxin A) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Mambalgin-1 | Apratoxin A |
|---|---|---|
| Category | Experimental | Experimental |
| Full Name | Mambalgin-1 from Dendroaspis polylepis venom | Apratoxin A |
| Molecular Weight | 6,300 Da | N/A |
| Half-Life | Minutes to hours | N/A |
| Amino Acids | 57 | N/A |
| Typical Dose | 0.1-1 nmol intrathecal|10-100 nM in vitro|single-dose rodent studies | N/A in humans; nanomolar in vitro |
| Route | Intrathecal | Intraperitoneal / Intravenous (preclinical) |
| Purity | ≥98% | ≥98% |
| Studies Count | 55 | 140 |
| Research Status | Pre-clinical | Pre-clinical |
Mambalgin-1 Benefits
- ✓ASIC channel inhibition
- ✓non-opioid analgesia research
- ✓sensory-neuron physiology
- ✓lead optimization for pain therapeutics
Apratoxin A Benefits
- ✓antineoplastic
- ✓anti-angiogenic
- ✓Sec61 inhibition
- ✓anti-proliferative
Mambalgin-1 Dosing
Intrathecal pain-behavior studies|ASIC1a/ASIC1b electrophysiology|Acute dosing in rodents
Apratoxin A Dosing
preclinical in vitro nanomolar use|animal studies only|no human dosing established
Mambalgin-1 Side Effects
- ⚠Hypoactivity at high dose
- ⚠off-target ASIC blockade
- ⚠local irritation
Apratoxin A Side Effects
- ⚠hepatotoxicity
- ⚠general cytotoxicity
- ⚠GI toxicity
Research Overview
Mambalgin-1
Pre-clinical work shows mambalgin-1 can reduce pain behaviors by modulating proton-gated ion channels in peripheral and central pathways. It has become an important template for developing ASIC-targeted analgesics.
Apratoxin A
Apratoxin A is a well-studied lead compound for targeting secretory and membrane protein biogenesis in cancer cells. Medicinal chemistry programs around apratoxins focus on improving selectivity and reducing hepatotoxicity while preserving potency.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.